Shared gene expression alterations in prostate cancer and histologically benign prostate from patients with prostate cancer.
暂无分享,去创建一个
George Vasmatzis | Farhad Kosari | J. Cheville | R. Karnes | C. Ida | F. Kosari | T. Sebo | G. Vasmatzis | A. Leontovich | R. Karnes | S. Murphy | S. Erdoğan | R Jeffrey Karnes | John C Cheville | Thomas J Sebo | Stephen J Murphy | Alexey A Leontovich | Sibel Erdogan | Cristiane M Ida | Erika Rodriguez | E. Rodriguez
[1] Deborah B. Thompson,et al. Subtle changes in benign tissue adjacent to prostate neoplasia detected with a Bayesian belief network , 1997, The Journal of pathology.
[2] M. Skobe,et al. Tumorigenic conversion of immortal human keratinocytes through stromal cell activation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[3] J. Mesirov,et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.
[4] A. Weaver,et al. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. , 2001, The Journal of urology.
[5] S. Dhanasekaran,et al. Delineation of prognostic biomarkers in prostate cancer , 2001, Nature.
[6] Ronglai Shen,et al. Changes in differential gene expression because of warm ischemia time of radical prostatectomy specimens. , 2002, The American journal of pathology.
[7] I. Leav,et al. Alpha-methylacyl-CoA racemase (P504S) expression in evolving carcinomas within benign prostatic hyperplasia and in cancers of the transition zone. , 2003, Human pathology.
[8] John D. Storey,et al. Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[9] Rajiv Dhir,et al. Differences in gene expression in prostate cancer, normal appearing prostate tissue adjacent to cancer and prostate tissue from cancer free organ donors , 2005, BMC Cancer.
[10] J. Jones,et al. Parasagittal biopsies add minimal information in repeat saturation prostate biopsy. , 2004, Urology.
[11] D. Landsittel,et al. Early identification of individuals with prostate cancer in negative biopsies. , 2004, The Journal of urology.
[12] Vijayalakshmi Ananthanarayanan,et al. Alpha‐methylacyl‐CoA racemase (AMACR) expression in normal prostatic glands and high‐grade prostatic intraepithelial neoplasia (HGPIN): Association with diagnosis of prostate cancer , 2005, The Prostate.
[13] C. D. Savci-Heijink,et al. Optimization of laser capture microdissection and RNA amplification for gene expression profiling of prostate cancer , 2007, BMC Molecular Biology.
[14] M. Skobe,et al. Platelet-derived growth factor-BB controls epithelial tumor phenotype by differential growth factor regulation in stromal cells. , 2006, The American journal of pathology.
[15] Ron Shamir,et al. Identification of functional modules using network topology and high-throughput data , 2007, BMC Systems Biology.
[16] Daniel W Lin,et al. Influence of surgical manipulation on prostate gene expression: implications for molecular correlates of treatment effects and disease prognosis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] C. Heldin,et al. PDGF receptors as targets in tumor treatment. , 2007, Advances in cancer research.
[18] J. Homsi,et al. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. , 2007, Cancer control : journal of the Moffitt Cancer Center.
[19] V. Kosma,et al. Hyaluronan in human tumors: pathobiological and prognostic messages from cell-associated and stromal hyaluronan. , 2008, Seminars in cancer biology.
[20] C. Betsholtz,et al. Paracrine signaling by platelet-derived growth factor-CC promotes tumor growth by recruitment of cancer-associated fibroblasts. , 2009, Cancer research.
[21] A. Poustka,et al. Molecular cancer phenotype in normal prostate tissue. , 2009, European urology.
[22] M. Lucia,et al. Prostate Cancer Detected by Methylated Gene Markers in Histopathologically Cancer-Negative Tissues from Men with Subsequent Positive Biopsies , 2009, Cancer Epidemiology, Biomarkers & Prevention.
[23] K. Butler,et al. Differential gene expression in tumor adjacent histologically normal prostatic tissue indicates field cancerization. , 2009, International journal of oncology.
[24] P. Sorensen,et al. The majority of total nuclear-encoded non-ribosomal RNA in a human cell is 'dark matter' un-annotated RNA , 2010, BMC Biology.
[25] C. Moreno. The Sex-determining region Y-box 4 and homeobox C6 transcriptional networks in prostate cancer progression: crosstalk with the Wnt, Notch, and PI3K pathways. , 2010, The American journal of pathology.
[26] Richard M. Karp,et al. DEGAS: De Novo Discovery of Dysregulated Pathways in Human Diseases , 2010, PloS one.
[27] G. Firestone,et al. BZL101, a phytochemical extract from the Scutellaria barbata plant, disrupts proliferation of human breast and prostate cancer cells through distinct mechanisms dependent on the cancer cell phenotype , 2010, Cancer biology & therapy.
[28] Nolwenn LeMeur,et al. Differential Gene Expression in Benign Prostate Epithelium of Men with and without Prostate Cancer: Evidence for a Prostate Cancer Field Effect , 2010, Clinical Cancer Research.
[29] Zhenyu Jia,et al. In silico estimates of tissue components in surgical samples based on expression profiling data. , 2010, Cancer research.
[30] Carolyn J. Brown,et al. The functional role of long non-coding RNA in human carcinomas , 2011, Molecular Cancer.